Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Calcimedica Inc's Business Segments
Calcimedica Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Calcimedica Inc
Calcimedica Inc is a biopharmaceutical company that focuses on the discovery and development of novel small molecule therapeutics to treat diseases associated with calcium dysregulation. The company was founded in 2007 and is headquartered in San Diego, California.
Calcium plays a vital role in the physiological processes of the human body, including muscle contraction, neurotransmitter release, and hormone secretion. However, dysregulation of calcium levels has been implicated in various diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases.
Calcimedica is on a mission to develop innovative therapies that target calcium channels, which are proteins responsible for regulating the influx and efflux of calcium ions across cellular membranes. By modulating these channels, Calcimedica aims to restore calcium homeostasis and potentially treat a wide range of diseases.
The company leverages its expertise in calcium signaling and drug discovery to identify and develop small molecule compounds that selectively modulate specific calcium channels. These compounds are designed to be highly specific, minimally toxic, and effective at targeting disease-associated calcium dysregulation.
Calcimedica's lead product candidate is CM4620, an orally available small molecule that targets the calcium-release activated calcium (CRAC) channel. Preclinical studies have demonstrated that CM4620 effectively inhibits CRAC channel activity, which is believed to be involved in the pathogenesis of various diseases, including autoimmune disorders and certain types of cancer.
In addition to CM4620, Calcimedica has an extensive pipeline of other calcium channel modulators at various stages of preclinical development. This pipeline includes compounds targeting other calcium channels, such as TRPV6, TRPM4, and TRPM7, which are implicated in diseases like prostate cancer, heart failure, and neuroinflammation.
Calcimedica adopts a strategic approach to drug development, which includes rigorous research, preclinical testing, and clinical trials to establish the safety and efficacy of its therapeutic candidates. The company collaborates with academic institutions, contract research organizations, and other industry partners to advance its compounds through the drug development process.
Overall, Calcimedica Inc is an innovative biopharmaceutical company dedicated to discovering and developing small molecule therapeutics that target calcium dysregulation. Their focus on calcium channels and their pipeline of potential drug candidates holds promise for the treatment of various diseases associated with calcium imbalances.
Calcium plays a vital role in the physiological processes of the human body, including muscle contraction, neurotransmitter release, and hormone secretion. However, dysregulation of calcium levels has been implicated in various diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases.
Calcimedica is on a mission to develop innovative therapies that target calcium channels, which are proteins responsible for regulating the influx and efflux of calcium ions across cellular membranes. By modulating these channels, Calcimedica aims to restore calcium homeostasis and potentially treat a wide range of diseases.
The company leverages its expertise in calcium signaling and drug discovery to identify and develop small molecule compounds that selectively modulate specific calcium channels. These compounds are designed to be highly specific, minimally toxic, and effective at targeting disease-associated calcium dysregulation.
Calcimedica's lead product candidate is CM4620, an orally available small molecule that targets the calcium-release activated calcium (CRAC) channel. Preclinical studies have demonstrated that CM4620 effectively inhibits CRAC channel activity, which is believed to be involved in the pathogenesis of various diseases, including autoimmune disorders and certain types of cancer.
In addition to CM4620, Calcimedica has an extensive pipeline of other calcium channel modulators at various stages of preclinical development. This pipeline includes compounds targeting other calcium channels, such as TRPV6, TRPM4, and TRPM7, which are implicated in diseases like prostate cancer, heart failure, and neuroinflammation.
Calcimedica adopts a strategic approach to drug development, which includes rigorous research, preclinical testing, and clinical trials to establish the safety and efficacy of its therapeutic candidates. The company collaborates with academic institutions, contract research organizations, and other industry partners to advance its compounds through the drug development process.
Overall, Calcimedica Inc is an innovative biopharmaceutical company dedicated to discovering and developing small molecule therapeutics that target calcium dysregulation. Their focus on calcium channels and their pipeline of potential drug candidates holds promise for the treatment of various diseases associated with calcium imbalances.
Calcimedica Inc. is a company that specializes in the development and provision of innovative healthcare solutions, primarily focused on osteoporosis and bone health management. Their offerings cover a range of segments, products, and services aimed at enhancing patient care and improving health outcomes. Here’s a detailed overview of their segments, products, and services:
Segments
1. Pharmaceuticals:
- Calcimedica develops and markets prescription medications specifically designed to enhance bone density and overall skeletal health. Their pharmaceutical segment often includes treatments for osteoporosis and other bone-related disorders.
2. Nutraceuticals:
- This segment includes dietary supplements that support calcium metabolism and overall bone health. Products typically feature a blend of vitamins, minerals, and other health-promoting ingredients designed to improve bone density and reduce the risk of fractures.
3. Medical Devices:
- Calcimedica is also involved in creating innovative medical devices that assist healthcare professionals in treating and managing bone health disorders. This could include diagnostic tools or devices that provide therapeutic benefits.
4. Digital Health Solutions:
- The company may offer digital health platforms that leverage technology to provide patient monitoring, education, and engagement tools, aiming to improve adherence to treatment regimens and promote healthier lifestyles.
Products
1. Prescription Therapies:
- Bisphosphonates:
- These are oral or injectable medications that inhibit bone resorption, thereby increasing bone density and reducing the risk of fractures.
- Hormonal Therapies:
- Certain hormonal treatments that can be prescribed for postmenopausal women or other specific populations at risk for osteoporosis.
2. Nutritional Supplements:
- Calcium and Vitamin D Supplements:
- Essential for maintaining bone health, supporting various functions in the body, and preventing deficiencies that could lead to osteoporosis.
- Collagen-based Products:
- Formulated to improve bone strength and joint health, often emphasizing the importance of collagen in maintaining structural integrity.
3. Medical Devices:
- Devices aimed at improving the assessment of bone density or health, which may include advanced imaging technology or screening tools that help diagnose osteoporosis or other bone conditions early.
4. Digital Applications:
- Mobile apps or online platforms that enable patients to track their medication adherence, exercise routines, nutritional intake, and other health parameters relevant to bone health management.
Services
1. Patient Education and Resources:
- Providing comprehensive and understandable information to patients and healthcare providers about bone health, treatment options, and lifestyle modifications that can support their overall well-being.
2. Healthcare Provider Support:
- Offering training and resources for healthcare professionals to effectively prescribe and manage treatments for osteoporosis and similar conditions. This may include workshops, seminars, or online training modules.
3. Clinical Insights and Research:
- Engaging in clinical trials and providing data-driven insights into the efficacy and safety of their products, which helps inform both clinical practice and product development.
4. Adherence Programs:
- Programs designed to improve patient adherence to prescribed treatment regimens. These might include reminders, tracking systems, and support networks to encourage consistent medication use and lifestyle changes.
5. Customized Treatment Plans:
- Collaborating with healthcare providers to develop personalized treatment plans that consider individual patient needs, preferences, and risk factors related to bone health.
Conclusion
Calcimedica Inc. positions itself as a comprehensive provider of solutions for bone health, focusing on an array of effective products and services that cater to the needs of patients and healthcare providers alike. Their commitment to research, education, and innovation ensures that they stay at the forefront of the healthcare landscape, continuously evolving to meet the changing needs of those at risk for osteoporosis and other bone health disorders.
Segments
1. Pharmaceuticals:
- Calcimedica develops and markets prescription medications specifically designed to enhance bone density and overall skeletal health. Their pharmaceutical segment often includes treatments for osteoporosis and other bone-related disorders.
2. Nutraceuticals:
- This segment includes dietary supplements that support calcium metabolism and overall bone health. Products typically feature a blend of vitamins, minerals, and other health-promoting ingredients designed to improve bone density and reduce the risk of fractures.
3. Medical Devices:
- Calcimedica is also involved in creating innovative medical devices that assist healthcare professionals in treating and managing bone health disorders. This could include diagnostic tools or devices that provide therapeutic benefits.
4. Digital Health Solutions:
- The company may offer digital health platforms that leverage technology to provide patient monitoring, education, and engagement tools, aiming to improve adherence to treatment regimens and promote healthier lifestyles.
Products
1. Prescription Therapies:
- Bisphosphonates:
- These are oral or injectable medications that inhibit bone resorption, thereby increasing bone density and reducing the risk of fractures.
- Hormonal Therapies:
- Certain hormonal treatments that can be prescribed for postmenopausal women or other specific populations at risk for osteoporosis.
2. Nutritional Supplements:
- Calcium and Vitamin D Supplements:
- Essential for maintaining bone health, supporting various functions in the body, and preventing deficiencies that could lead to osteoporosis.
- Collagen-based Products:
- Formulated to improve bone strength and joint health, often emphasizing the importance of collagen in maintaining structural integrity.
3. Medical Devices:
- Devices aimed at improving the assessment of bone density or health, which may include advanced imaging technology or screening tools that help diagnose osteoporosis or other bone conditions early.
4. Digital Applications:
- Mobile apps or online platforms that enable patients to track their medication adherence, exercise routines, nutritional intake, and other health parameters relevant to bone health management.
Services
1. Patient Education and Resources:
- Providing comprehensive and understandable information to patients and healthcare providers about bone health, treatment options, and lifestyle modifications that can support their overall well-being.
2. Healthcare Provider Support:
- Offering training and resources for healthcare professionals to effectively prescribe and manage treatments for osteoporosis and similar conditions. This may include workshops, seminars, or online training modules.
3. Clinical Insights and Research:
- Engaging in clinical trials and providing data-driven insights into the efficacy and safety of their products, which helps inform both clinical practice and product development.
4. Adherence Programs:
- Programs designed to improve patient adherence to prescribed treatment regimens. These might include reminders, tracking systems, and support networks to encourage consistent medication use and lifestyle changes.
5. Customized Treatment Plans:
- Collaborating with healthcare providers to develop personalized treatment plans that consider individual patient needs, preferences, and risk factors related to bone health.
Conclusion
Calcimedica Inc. positions itself as a comprehensive provider of solutions for bone health, focusing on an array of effective products and services that cater to the needs of patients and healthcare providers alike. Their commitment to research, education, and innovation ensures that they stay at the forefront of the healthcare landscape, continuously evolving to meet the changing needs of those at risk for osteoporosis and other bone health disorders.